| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.009 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.02 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.03 |